profit from every $100 of sales.
$0$100
Grifols
$8.69-1.25% today
-0.1% in 1 year
1-year low $7.021-year high $9.72
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $13.34 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Grifols sold, what it kept, and what it did with the cash.
Sales went from €6.06 billion in 2022 to €7.52 billion in 2025, with €402 million of profit last year.
SalesProfit
Grifols handed back 21% of the cash it generated last year.
€128M
Free cash flow 2025€624M
Bought back its own shares–
Paid as dividends€128M
Cash vs. debt€801M vs. €9.6B
Grifols vs. similar companies
Grifols grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Grifols | 13.3× · Cheap | ||
 Eli Lilly | 62.3× · Very expensive | ||
 Johnson & Johnson | 25.7× · Fair price | ||
 AbbVie | 123.4× · Very expensive | ||
 Roche | 25.5× · Fair price |
AI analysis
An AI analyst reads Grifols's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 6,064 | 6,592 | 7,212 | 7,524 | |
| 2,214 | 2,483 | 2,794 | 2,859 | |
| 679 | 718 | 1,155 | 1,251 | |
| 1,194 | 1,168 | 1,484 | 1,641 | |
| 185 | 42 | 157 | 402 | |
| 0.31 | 0.09 | 0.23 | 0.59 | |
| 36.5% | 37.7% | 38.7% | 38.0% | |
| 11.2% | 10.9% | 16.0% | 16.6% | |
| 3.1% | 0.6% | 2.2% | 5.3% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 21,230 | 20,992 | 21,405 | 19,712 |
| Cash | 549 | 530 | 980 | 801 |
| Total debt | 9,750 | 10,973 | 10,113 | 9,566 |
| Total liabilities | 13,253 | 13,478 | 12,799 | 12,109 |
| 5,649 | 5,368 | 5,883 | 5,271 | |
| 680 | 680 | 680 | 682 | |
| 4.0% | 3.5% | 5.2% | 6.3% | |
| 3.3% | 0.8% | 2.7% | 7.6% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -1 | 217 | 902 | 1,047 | |
| 393 | 310 | 372 | 423 | |
| -394 | -93 | 530 | 624 | |
| Dividends paid | 1 | 0 | 1 | 128 |
| 3 | 0 | 0 | – | |
| – | – | – | – |
Valuation
- 13.3×
- 9.9×
- 0.56
- 1.0×
- 0.7×
- 8.6×
- 8.6×
- 11.6%
- 7.5%
- 2.4%
Profitability
- 38.0%
- 16.6%
- 5.3%
- 19.3%
- 6.5%
- 4.9%
- 7.9%
- 2.1%
- 7.0%
- 5.6%
Growth
- +7.5%
- +23.9%
- +41.5%
- +4.2%
- +0.1%
Financial health
- 5.3×
- 1.81
- 48.2%
- 2.1×
- 2.51
- 0.85
- 0.37
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 45%of 952
Top 30%of 884
Top 18%of 601
Bottom 40%of 886
Top 5%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 0.17 | 0.16 | +7.3% |
| Feb 26, 2026 | 0.29 | 0.29 | −0.3% |
| Nov 4, 2025 | 0.22 | 0.24 | −9.6% |
| Jul 28, 2025 | 0.19 | 0.23 | −17.4% |
| May 12, 2025 | 0.10 | 0.14 | −28.6% |
| Mar 6, 2025 | 0.26 | 0.13 | +100.0% |
| Nov 7, 2024 | 0.16 | 0.22 | −27.3% |
| Jul 30, 2024 | 0.02 | 0.23 | −91.3% |
2.4%of the share price, paid each year
On $1,000 invested$24a year at today's yield, before tax
+4.2%2020 to 2025
Raised–not every year
Paid per share, each year
$0.29 in 2017 → $0.18 in 2025
How safe it looks
31.8% of its profit
Room to growStretchedMore than it earns: 20.5%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/7Passes 3 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
53No pass
Benjamin Graham
77Pass
Philip Fisher
60Pass
Peter Lynch
71Pass
Joel Greenblatt
40No pass
Charlie Munger
38No pass
Terry Smith
44No pass
Questions about Grifols
Is Grifols a good stock to buy?
A business with weak numbers, and the price looks low. 3 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Grifols AI analysis
What does Grifols do?
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It is in Drug Manufacturers - General, based in Barcelona, Spain, with 25,000 employees.
Does Grifols pay a dividend?
Yes. At today's price the dividend is 2.4% a year, about 32% of its yearly profit. In 2025 it paid out $128 million in dividends.
Is Grifols stock halal?
No. Grifols does not pass our halal screen: its debt is 178% of its market value, at or above the 33% limit. How we check
How has Grifols stock done over the past year?
Down 0.1% over the past twelve months, to $8.69. It traded between $7.02 and $9.72 and is 10.6% below its high.
Who are Grifols's competitors?
The largest listed companies in the same industry are Eli Lilly, Johnson & Johnson, AbbVie and Roche. The peers table on this page compares their profit, growth and price with Grifols's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.